Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors
about
HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT InhibitorsHIV-1 subtype B protease and reverse transcriptase amino acid covariationDifferential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CCharacterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian exampleCharacterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Transmitted antiretroviral drug resistance and thumb subdomain polymorphisms among newly HIV type 1 diagnosed patients infected with CRF01_AE and CRF07_BC virus in Guangdong Province, China.New subtypes and genetic recombination in HIV type 1-infecting patients with highly active antiretroviral therapy in Peru (2008-2010)Short communication: Nucleotide variation and positively selected sites in HIV type 1 reverse transcriptase among heterosexual transmission pairsA counting renaissance: combining stochastic mapping and empirical Bayes to quickly detect amino acid sites under positive selectionBayesian network analyses of resistance pathways against efavirenz and nevirapine.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTTreatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.HIV-1 mutational pathways under multidrug therapy.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityClinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapySpecific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
P2860
Q27670634-25BE4B97-11F6-4264-B894-8118B2FD26FCQ28469203-2746FF9C-99AB-498D-8382-D62E2C496732Q28484213-842875DD-6EAB-4FDC-BE07-581B46B4C2E5Q33483060-0B537B52-4EAF-4696-9913-6C566CEDC0F3Q33514943-D99FF299-C258-4E2F-9E38-3F3018EDDD13Q33624190-92E3D974-D844-479E-8D7D-19855C0E7DFDQ35843775-2A8E580F-0898-428C-A7AF-DE6E21B67AD2Q36099251-90438A3D-A621-4CC5-9162-A713900F69D2Q36292765-FF7F81F3-361F-4F15-B146-E5E12CA9E83DQ36419468-E7AF999C-D83A-4A5E-B814-A76F387054E2Q36429586-6730FA48-2A93-4B34-8791-BA7BC2B981F3Q36433533-D644A622-C711-44C8-9D58-88C9947A4A35Q36629197-D8388600-37EF-4475-BD1C-14C5AC0DA5B8Q36677558-ECB5EC5F-CA7E-4258-B7F0-484C85370473Q36900010-23AEFCFF-5438-4459-8539-9842F7A31EEAQ37247695-3B7DCB1A-12D2-4E5D-BF56-3E87978782AEQ37256719-22DEE112-F9D6-4741-B4B1-16AC9C046D93Q37405816-ED13C7F2-772D-49FB-9304-037E1F03992DQ37538534-0D329D03-7B46-43DF-84AC-27B64A95694AQ38264403-A9C40D2B-E636-4ED1-A0C1-A8E455A653F2Q39142877-7C24D70F-765E-4CDB-9EBD-6AB579204169Q39664167-F11012B0-C8E8-4399-A4E7-8A7814C8A158Q40013658-A9CEE1D1-FFBB-4BB7-B95A-617BEED6724EQ41504610-A29498BB-F7F4-4162-86E9-001859F6C541Q41720036-84905FE3-616A-4540-9C29-D5962EDB8C18Q42151695-528890A2-B021-4CEF-A86E-4C2D2D9DD832Q42430831-615EA2E7-A8C1-4A0F-965B-E99AC44CE727Q42917410-CCA4B9F4-718B-4CE5-A871-1EC1C6885C69Q44113439-68E2F822-ECDA-49C1-BCA4-ED445B5E8576Q46230871-B3A71EEE-6933-4AAC-AF72-4248AE1AC8FEQ54567693-4E13CE94-E8F4-4DC9-BCC0-FA89F3989615
P2860
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Involvement of novel human imm ...... tance to nucleoside inhibitors
@ast
Involvement of novel human imm ...... tance to nucleoside inhibitors
@en
Involvement of novel human imm ...... tance to nucleoside inhibitors
@nl
type
label
Involvement of novel human imm ...... tance to nucleoside inhibitors
@ast
Involvement of novel human imm ...... tance to nucleoside inhibitors
@en
Involvement of novel human imm ...... tance to nucleoside inhibitors
@nl
prefLabel
Involvement of novel human imm ...... tance to nucleoside inhibitors
@ast
Involvement of novel human imm ...... tance to nucleoside inhibitors
@en
Involvement of novel human imm ...... tance to nucleoside inhibitors
@nl
P2093
P2860
P50
P356
P1433
P1476
Involvement of novel human imm ...... tance to nucleoside inhibitors
@en
P2093
Federigo Gago
Fátima Rodríguez-Barrios
Maria Concetta Bellocchi
Tobias Sing
Valentina Svicher
P2860
P304
P356
10.1128/JVI.02084-05
P407
P50
P577
2006-07-01T00:00:00Z